Which of the following is the most effective preventive strategy to reduce bleeding episodes in patients with hemophilia?
সমাধান
সঠিক উত্তর: Option B
The most effective preventive strategy to reduce bleeding episodes in patients with hemophilia is prophylactic factor replacement therapy.
Hemophilia is a congenital bleeding disorder characterized by a deficiency in clotting factors, most commonly factor VIII (Hemophilia A) or factor IX (Hemophilia B). The underlying problem is an inability to form stable blood clots, leading to recurrent bleeding episodes, particularly into joints and muscles.
Prophylactic factor replacement therapy involves the regular administration of the deficient clotting factor before bleeding occurs. This approach significantly reduces the frequency and severity of bleeding episodes, prevents joint damage (arthropathy), and improves the patient's quality of life. It is considered the standard of care, especially in severe hemophilia.
The other options are less effective for prevention:
- Antifibrinolytic therapy with tranexamic acid is useful as an adjunct treatment to stabilize formed clots, primarily in mucosal bleeding (e.g., dental procedures) but does not replace missing clotting factors nor prevent spontaneous bleeds.
- Desmopressin administration is effective only in mild Hemophilia A because it stimulates the release of endogenous factor VIII and von Willebrand factor but is not helpful in severe cases or Hemophilia B.
- Vitamin K supplementation is not effective because hemophilia is not caused by vitamin K deficiency; the clotting factors involved are not vitamin K-dependent.
In summary, prophylactic factor replacement therapy directly addresses the deficiency causing hemophilia and thus is the most effective preventive strategy.
Reference: Harrison's Principles of Internal Medicine, 20th Edition, Volume 2, Chapter 327: Coagulation Disorders, Page 2389-2393
Hemophilia is a congenital bleeding disorder characterized by a deficiency in clotting factors, most commonly factor VIII (Hemophilia A) or factor IX (Hemophilia B). The underlying problem is an inability to form stable blood clots, leading to recurrent bleeding episodes, particularly into joints and muscles.
Prophylactic factor replacement therapy involves the regular administration of the deficient clotting factor before bleeding occurs. This approach significantly reduces the frequency and severity of bleeding episodes, prevents joint damage (arthropathy), and improves the patient's quality of life. It is considered the standard of care, especially in severe hemophilia.
The other options are less effective for prevention:
- Antifibrinolytic therapy with tranexamic acid is useful as an adjunct treatment to stabilize formed clots, primarily in mucosal bleeding (e.g., dental procedures) but does not replace missing clotting factors nor prevent spontaneous bleeds.
- Desmopressin administration is effective only in mild Hemophilia A because it stimulates the release of endogenous factor VIII and von Willebrand factor but is not helpful in severe cases or Hemophilia B.
- Vitamin K supplementation is not effective because hemophilia is not caused by vitamin K deficiency; the clotting factors involved are not vitamin K-dependent.
In summary, prophylactic factor replacement therapy directly addresses the deficiency causing hemophilia and thus is the most effective preventive strategy.
Reference: Harrison's Principles of Internal Medicine, 20th Edition, Volume 2, Chapter 327: Coagulation Disorders, Page 2389-2393